Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-04-26
2011-04-26
Lucas, Zachariah (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S184100, C424S278100
Reexamination Certificate
active
07932367
ABSTRACT:
The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
REFERENCES:
patent: 5149798 (1992-09-01), Agrawal et al.
patent: 6028183 (2000-02-01), Lin et al.
patent: 6365730 (2002-04-01), Jennings et al.
patent: 6562798 (2003-05-01), Schwartz
patent: 7105495 (2006-09-01), Agrawal et al.
patent: 7115579 (2006-10-01), Agrawal et al.
patent: 7176296 (2007-02-01), Agrawal et al.
patent: 7276489 (2007-10-01), Agrawal et al.
patent: 7405285 (2008-07-01), Agrawal et al.
patent: 7407944 (2008-08-01), Agrawal et al.
patent: 7427405 (2008-09-01), Agrawal et al.
patent: 7470674 (2008-12-01), Agrawal et al.
patent: 7498425 (2009-03-01), Agrawal et al.
patent: 7517862 (2009-04-01), Agrawal et al.
patent: 2004/0097719 (2004-05-01), Agrawal et al.
patent: 2004/0198685 (2004-10-01), Agrawal et al.
patent: 2005/0009773 (2005-01-01), Kandimalla et al.
patent: 2005/0026861 (2005-02-01), Kandimalla et al.
patent: 2006/0019918 (2006-01-01), Agrawal et al.
patent: 2006/0019919 (2006-01-01), Agrawal et al.
patent: 2006/0025365 (2006-02-01), Agrawal et al.
patent: 2006/0094680 (2006-05-01), Agrawal et al.
patent: 2006/0094681 (2006-05-01), Agrawal et al.
patent: 2006/0211641 (2006-09-01), Agrawal et al.
patent: 2006/0217328 (2006-09-01), Kandimalla et al.
patent: 2006/0287261 (2006-12-01), Agrawal et al.
patent: 2006/0287262 (2006-12-01), Agrawal et al.
patent: 2007/0072198 (2007-03-01), Kandimalla et al.
patent: 2007/0093439 (2007-04-01), Agrawal et al.
patent: 2008/0152662 (2008-06-01), Agrawal et al.
patent: 2008/0193437 (2008-08-01), Agrawal et al.
patent: 2008/0206265 (2008-08-01), Kandimalla et al.
patent: WO99/62923 (1999-12-01), None
Chaix et al (1996) Bioorganic & Medicinal Chemistry Letters. 6(7): 827-832.
Smee et al (1991) Antimicrobial Agent and Chemotherapy. 35(1): 152-157.
Schneider and Chait (1995) Nucleic Acids Research. 23(9): 1570-1575.
Khorana et al. (1972) “Studies on Polynucleotides,”J. Molec. Biol. 72:209.
Reese (1978) “The Chemical Synthesis of Oligo- and Poly-Nucleotides by the Phosporotrlester Approach,”Tetrahedron34:3143-3179.
Beaucage et al. (1981) “Deoxynucleoside Phosphoramidites—A New Class of Key intermediates for Deoxypolynucleotide Synthesis,”Tetrahedron Lett. 22:1859-1862.
Connolly et al. (1984) “Synthesis and Characterization of an Octanucleotide Containing theEcoRl Recognition Sequence With A Phosphorothioate Group At the Cleavage Site,” Biochemistry 23:3443.
Agrawal et al. (1987) “Oligodeoxynucleotise Methylphosphonates: Synthesis and Enzymic Degradation,”Tetrahedron Lett. 28(31):3539-3542.
Jager et al. (1988) OligonucleotideN-Alkylphosphoroamidates: Synthesis and Binding to Polynucleotides,Biochemistry27:7237.
Agrawal et al. (1988) Oligodeoxynucleoside Phosphoroamidates and Phosporothioates As Inhibitors of Human Immunodeficiency Virus,Proc. Natl. Acad. Sci. USA85:7079-7083.
Zon et al. (1991) “Phosphorothioate Oligonculeotides”Oligonucleotides and Analogues: A Practical Approachpp. 87-108.
Kuramoto et al. (1992) “Oligonucleotide Sequences Required for Natural Killer Cell Activation,”Jpn. J. Cancer Res. 83:1128-1131.
Crooke (1993) “An Overview of Progress in Antisense Therapeutics,” 8Antisense & Nucl. Acid Drug Dev. 115-122 CRC Press, Boca Raton, Florida.
Zon (1993) “Protocols for Oliognucleotides and Analogs,”Methods in Molecular Biologyvol. 20, pp. 165-189.
Pisetsky et al. (1994)“Stimulation of Murine Lymphocyte Proliferation by a Phosphorothioate Oligonucleotide With Antisense Activity for Herpes Simplex Virus,” 54Life Sci. 101.
Yamamoto et al. (1994) “Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence of AACGTT to Murine Spenocytes Enhances Interferon Production and Natural Killer Activity,” 38Microbiol. Immunol.831.
Agrawal et al. (1995) “Modified Oligonucleotides as Therapeutic and Diagnostic Agents,”Curr.Opin.Biotechnol. 6:12-19.
Krieg et al. (1995) “CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation,”Nature371:546-549.
Klinman et al. (1996) “CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interferon γ,” 93Proc. Natl. Acad. Sci. USA2879.
Liang et al. (1996) “Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides,”J. Clin. Invest. 98:1119-1129.
Zhao et al. (1996) “Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation,”Biochem. Pharm. 51:173-182.
Chu et al. (1997) “CpG Oligodeoxynucleotides Act As Adjuvants That Switch on T Helper 1 (Th1) Immunity,” 186J. Exp. Med. 1623.
Dunford et al. (1997) “Antisense 97: Targeting the Molecular Basis of Disease” (Nature Biotechnology)Conference Abstract, pp. 40.
Sparwasser et al. (1997) “Macrophages Sense Pathogens Via DNA Motifs: Induction of Tumor Necrosis Factor-α-Mediated Shock,” 27 Eur. J. Immunol. 1671.
Zhao et al. (1997) “Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotides in Mice,” 7Antisense Nucleic Acid Drug. Dev. 495.
McCluside et al. (1998) “Cutting Edge: CpG DNA Is A Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice,”J. Immunol. 161:4463-4466.
Moldoveanu et al. (1998) “CpG DNA, A Novel Immune Enhancer for Systemic and Mucosal Immunization With Influenza Virus,”Vaccine16:1216-1224.
Sparwasser et al. (1998) “Bacterial DNA and Immunostimulatory CpG Oligonucleotides Trigger Maturation and ACtivation of Murine Dendritic Cells,” 28Eur. J. Immunol. 2045.
Tokunaga et al. (1999) “How BCG Led to the Discovery of Immunostimulatory DNA,” 52Jap. J. Infect. Dis. 1.
Zhao et al. (1999) “Site of Chemical Modifications in CpG Containning Phosphorothioate Oligodeoxynucleotide Modulates Its Immunostimulatory Activity,”Bioorg.&Med. Chem. Lett. 9:3453-3458.
Agrawal et al. (2000) “Antisense Therapeutics: Is It As Simple As Complementary Base Recognition,” 6Mol. Med. Today72.
Zhao et al. (2000) “Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside,”Bioorg.&Med. Chem. Lett. 10:1051-1054.
Agrawal et al., “Antisense therapeutics”, Curr. Opin. Chem. Biol., 2:519-528, 1998.
Chaix et al., “3'-3' Linked Oligonucleotides: Synthesis and Stability Studies”, Biorg. & Med. Chem., 6:827-832, 1996.
Klinman, “therapeutic Applications of CpG-Containing Oli-Godeoxynucleotides”, Antisense & Nucl. Acid Drug Dev., 8:181-184, 1998.
Yu et al., “Accessible 5'-End of CpG-Containing . . . ”, Bioorganic & Medicinal Chemistry Lett., 10:2585-2588, 2000.
Kandimalla et al., “Effect of Chemical Modifications . . . ”, Bioorganic & Medicinal Chemistry, 9:807-813, 2001.
International Search Report (PCT App. No. PCT/US01/30137).
Agrawal Sudhir
Kandimalla Ekambar R.
Yu Dong
Zhao Qiuyan
Daptula Furman Gregory
Horning Michelle
Idera Pharmaceuticals Inc.
Keown Wayne A.
Lucas Zachariah
LandOfFree
Modulation of immunostimulatory activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of immunostimulatory activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of immunostimulatory activity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663455